Summary
Merck & Co., Inc. reported solid financial results for the second quarter and first six months of 2017, demonstrating resilient top-line growth and significant improvement in profitability. Total sales increased by 1% to $9.9 billion for the second quarter and $19.4 billion for the first six months, driven by strong performance in oncology, particularly Keytruda, alongside growth in vaccines and animal health products. This growth was partially offset by declines in key cardiovascular and diabetes medications due to generic competition and pricing pressures. Profitability saw a substantial improvement, with net income increasing by 61% to $1.9 billion in the second quarter and 50% to $3.5 billion in the first six months. This was primarily due to lower costs, including reduced spending on materials and production, and a decrease in research and development expenses. The company also highlighted strategic advancements, notably a significant global oncology collaboration with AstraZeneca for Lynparza and selumetinib, signaling a continued commitment to expanding its oncology portfolio. However, the company also disclosed a cyber-attack in late June that impacted operations, though it maintained confidence in the supply of key products.
Financial Highlights
51 data points| Revenue | $9.93B |
| Cost of Revenue | $3.08B |
| Gross Profit | $6.85B |
| R&D Expenses | $1.78B |
| SG&A Expenses | $2.50B |
| Interest Expense | $193.00M |
| Net Income | $1.95B |
| EPS (Basic) | $0.71 |
| EPS (Diluted) | $0.71 |
| Shares Outstanding (Basic) | 2.73B |
| Shares Outstanding (Diluted) | 2.75B |
Key Highlights
- 1Merck reported a 1% increase in worldwide sales to $9.9 billion for Q2 2017 and $19.4 billion for the first six months of 2017, driven by Keytruda, Zepatier, and vaccine sales.
- 2Net income attributable to Merck & Co., Inc. saw significant growth, up 61% to $1.9 billion in Q2 2017 and 50% to $3.5 billion for the first six months.
- 3The company entered into a major global oncology collaboration with AstraZeneca to co-develop and co-commercialize Lynparza and selumetinib, involving an upfront payment of $1.6 billion and potential milestone payments up to $8.5 billion.
- 4Sales of Keytruda, the company's flagship oncology drug, more than doubled, reaching $881 million in Q2 2017 and $1.5 billion in the first six months, reflecting broad market uptake and new indications.
- 5Restructuring costs decreased, contributing to improved profitability, with the company expecting to substantially complete remaining restructuring actions by the end of 2017.
- 6A significant cyber-attack occurred in late June 2017, disrupting operations; however, Merck stated it largely restored packaging and formulation operations and expected minimal impact on sales of top products.
- 7Sales of Zetia and Vytorin experienced substantial declines due to U.S. market exclusivity losses and generic competition, with sales down 40% and 36% for Q2 and year-to-date respectively.